More Arovella Therapeutics Limited news
Arovella Therapeutics LimitedASX: ALA

Preclinical trial of ALA iNKT therapy and IMU onCARlytics

Sep 26, 2022 at 12:16 AM EDT · Issued by Arovella Therapeutics Limited

Filed with ASX · Sep 26, 2022 at 12:16 AM EDT · 4 pages · English

On 6ix: 6ix.com/news/preclinical-trial-of-ala-inkt-therapy-and-imu-oncarlytics

Arovella Therapeutics Limited on 6ix

In the deck

  • Arovella Therapeutics — Investor Presentation (September 2022)36 slidesSep 26, 2022

Earlier from Arovella Therapeutics

  • Preliminary Final ReportAug 31, 2022
  • Quarterly Appendix 4C and Activities ReportJul 28, 2022
  • Sumatriptan UpdateJun 27, 2022
  • ZolpiMist Launch AustraliaJun 22, 2022
  • Adopts WEF Framework For ESG ReportingJun 7, 2022

Later from Arovella Therapeutics

  • Arovella to close its Perth OroMist R&D FacilityOct 25, 2022
  • Europe Patent granted for iNKT Cell Therapy PlatformNov 6, 2022
  • R&D Tax Incentive refund receivedNov 29, 2022
  • Arovella completes $1.65M placementJan 18, 2023
  • ALA-101 confers survival benefit in leukemia modelApr 16, 2023
All Arovella Therapeutics news releases↗

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer